The deal includes a vaccine adapted to the Omicron variant, and is expected to be licensed, according to Pfizer.
Pfizer Inc. and BioNTech announced yesterday that they have signed a $ 3.2 billion (€ 3.6 billion) financial agreement with the US government to supply 105 million doses of their COVID-19 vaccine.
The installments are expected to be delivered by the end of the summer.
The agreement includes one vaccine adapted to the Omicron variant, while the relevant license is expected, according to Pfizer.
Manufacturers of COVID-19 vaccines, including Pfizer, are developing vaccines targeting the Omicron variant, which dominated the spread of infections last winter, causing a massive increase in cases.
The average installment price provided in the agreement exceeds $ 30 (28.71 euros). This is an increase of more than $ 19.50 (€ 18.66) per installment, paid by the US government in its initial contract with Pfizer.
Some of the adult doses included in this contract will be in single-dose vials, which have higher mass production costs but reduce dose losses from vials already opened for use.
U.S. Food and Drug Administration advisers have proposed a change in the planning of COVID-19 boost doses this fall to combat more recent coronavirus strains.
Check out the news feed and stay up to date with the latest news.
